Continuous glucose monitor

Global Diabetes Care Devices Market Analysis/Forecasts Report 2022: A $42 Billion Market by 2028 - Rapid Technological Advancements in Diabetes Care Devices - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022

However, the high cost of diabetes care devices is hampering the global diabetes care devices market growth

Key Points: 
  • However, the high cost of diabetes care devices is hampering the global diabetes care devices market growth
    Technological advancements in the healthcare industry are encouraging market players to focus on research and development of insulin delivery devices.
  • The continuous research in insulin pens supports the growth of the global diabetes care devices market during the forecast period.
  • The diabetes care devices allow diabetes patients to monitor and manage their diabetes in their homes.
  • The prevalence of type 1 diabetes patients is likely to fuel the demand for diabetes care devices.

Global Digital Diabetes Management Market Report 2022: Rise of Disease Management Smartphone Apps Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022

The "Digital Diabetes Management Market Size, Share & Trends Analysis Report by Product (Continuous Blood Glucose Monitoring System, Smart Insulin Pen), by Type, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Digital Diabetes Management Market Size, Share & Trends Analysis Report by Product (Continuous Blood Glucose Monitoring System, Smart Insulin Pen), by Type, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global digital diabetes management market size is expected to reach USD 21.90 billion by 2030, according to this report.
  • The number of smartphone apps for disease management has seen a monumental rise over the past few years, giving the market a major boost.
  • The market growth is further augmented by the increasing prevalence of obesity, the growing aging population, and increasing awareness regarding diabetes preventive care.

2022 Continuous Glucose Monitoring Systems Market Report: A $4.43 Bn Market in 2021 - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 22, 2022

The "Continuous Glucose Monitoring Systems Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Glucose Monitoring Systems Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Continuous Glucose Monitoring Systems Market is projected to reach USD 8,794.97 million by 2027 from USD 4,432.35 million in 2021, at a CAGR 12.09% during the forecast period.
  • The report on continuous glucose monitoring systems identifies key attributes about the customer to define the potential market and identify different needs across the industry.
  • The Americas Continuous Glucose Monitoring Systems Market size was estimated at USD 1,335.31 million in 2021, is expected to reach USD 1,480.39 million in 2022, and is projected to grow at a CAGR of 11.78% to reach USD 2,605.00 million by 2027.

Global Insulin Pumps and Continuous Glucose Monitors Market Insights to 2030 - Players Include Medtronic, DexCom, Abbott Laboratories and Ypsomed Holdings - ResearchAndMarkets.com

Retrieved on: 
Friday, July 8, 2022

The model discusses in detail the impact of COVID-19 on Insulin Pumps and Continuous Glucose Monitors Devices market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Insulin Pumps and Continuous Glucose Monitors Devices market for the year 2020 and beyond.
  • People with insulin-dependent diabetes require intensive insulin therapy to manage their blood glucose levels within a healthy range.
  • Insulin can be delivered by syringes and vials, insulin pumps, and insulin pens.
  • Insulin Pumps include Traditional Insulin Pumps & Accessories and Patch Pumps.

Rimidi Expands Team by 86%, Grows Revenue by 100% in First Half of 2022

Retrieved on: 
Wednesday, July 6, 2022

ATLANTA, July 6, 2022 /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today that the company has expanded its employee base by 86% and seen a 100% growth in revenue, accompanied by an enlargement of its Atlanta headquarters. The overarching company growth and momentum further underscores Rimidi's commitment and ability to create innovative solutions for its hospital, health system, and provider customers that result in better workflows, experiences, and outcomes.

Key Points: 
  • Rimidi continues to be a leader in enterprise software for chronic disease management and clinical workflow optimization, including remote patient monitoring and clinical decision support.
  • Recent additions to the team will further support the company in developing a sustainable product roadmap and a secure, scalable software platform.
  • "Our employee growth across quality, compliance, product and client success is pivotal to achieving this goal."
  • Heading into the second half of 2022, Rimidi has additional product and technology developments planned, including new disease modules, device integrations, and EHR partners.

ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

Retrieved on: 
Wednesday, June 29, 2022

Ltd (ALRT or the Company) (OTCQB: ALRT), the diabetes management company, announces the completion of a definitive manufacturing agreement with Infinovo Medical Co. Ltd (Infinovo) to manufacture and supply the Continuous Glucose Monitor (CGM) hardware that will be utilized as part of the ALRT GluCurve Pet CGM (the Manufacturing Agreement).

Key Points: 
  • Ltd (ALRT or the Company) (OTCQB: ALRT), the diabetes management company, announces the completion of a definitive manufacturing agreement with Infinovo Medical Co. Ltd (Infinovo) to manufacture and supply the Continuous Glucose Monitor (CGM) hardware that will be utilized as part of the ALRT GluCurve Pet CGM (the Manufacturing Agreement).
  • The Manufacturing Agreement gives ALRT the exclusive global rights to distribute the Infinovo CGM hardware for the animal health market, providing long-term production and supply.
  • Our next targeted milestone is securing distribution for the ALRT GluCurve Pet CGM.
  • See the Form 8-K filed May 20, 2022, by ALR Technologies Inc. for further information about the Redomicile Merger Agreement.

GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor

Retrieved on: 
Wednesday, June 22, 2022

In early Q2 the Company completed lab testing of its Gen 2 clinical prototype system.

Key Points: 
  • In early Q2 the Company completed lab testing of its Gen 2 clinical prototype system.
  • This process included testing of multiple iterations of electronics, ear clip, and mobile app with cloud-based software.
  • The completion of bench testing and analyses of the Gen 2 clinical prototype system was followed by simulated use testing.
  • Initial data collected indicates that the Gen 2 system may achieve an accuracy comparable to invasive Continuous Glucose Monitors (CGMs) currently available in the market when conducting the upcoming first in-human clinical study.

Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor

Retrieved on: 
Sunday, June 5, 2022

"Abbott revolutionized glucose monitoring with our world-leading FreeStyle Libre technology -- the first sensor to eliminate painful fingersticks by offering factory-calibrated continuous glucose monitoring that is affordable, accessible and accurate," said Mahmood Kazemi, M.D., divisional vice president, global medical affairs and chief medical officer of Abbott's diabetes care business. "A sub-8% overall MARD for the FreeStyle Libre 3 system is a significant milestone, not just in terms of CGM innovation, but because it empowers people with diabetes to be more confident when making important diabetes management decisions."

Key Points: 
  • The multi-centerstudy evaluated the accuracy of the FreeStyle Libre 3 system in people with type 1 or type 2 diabetes, aged 4 or older, who were on insulin therapy.
  • FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.
  • Failure to use FreeStyle Libre 3 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.
  • 1Alva S, Brazg R, Castorino K, Liljenquist D, Liu H, and Kipnes M. Performance of the FreeStyle Libre 3 System.

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System

Retrieved on: 
Friday, June 3, 2022

"We're designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution.

Key Points: 
  • "We're designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution.
  • Recent studies show continuous ketone monitoring (CKM) could help prevent DKA.3 With continuous monitoring, rising ketone levels can be detected early, as a warning of impending ketoacidosis, and inform care so that DKA does not develop.
  • Abbott is already conducting clinical studies on the glucose-ketone monitoring system.
  • Abbott plans to partner with leading insulin pump manufacturers to make the dual monitoring system interoperable with insulin delivery systems.

Abbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor

Retrieved on: 
Tuesday, May 31, 2022

If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions.

Key Points: 
  • If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions.
  • At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.
  • Based on a comparison of list prices of the FreeStyle Libre 3 system versus previous generations of FreeStyle Libre Personal CGM systems.
  • At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.